candesartan cilexetil Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
angiotensin II receptor antagonists, antihypertensive (non-peptidic) 475 145040-37-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • candesartan cilexetil
  • TCV-116
  • TCV 116
a nonpeptide angiotensin II receptor antagonist
  • Molecular weight: 610.67
  • Formula: C33H34N6O6
  • CLOGP: 7.08
  • LIPINSKI: 3
  • HAC: 12
  • HDO: 1
  • TPSA: 143.34
  • ALOGS: -5.48
  • ROTB: 13

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 4 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.05 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.61 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
June 4, 1998 FDA ASTRAZENECA
March 12, 1999 PMDA Takeda Pharmaceutical Company Limited

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute kidney injury 412.41 10.18 952 65927 252916 53029271
Hyponatraemia 379.42 10.18 567 66312 108040 53174147
General physical health deterioration 215.22 10.18 530 66349 146412 53135775
Drug ineffective 185.13 10.18 477 66402 816768 52465419
Hyperkalaemia 177.52 10.18 275 66604 53981 53228206
Product dose omission issue 132.45 10.18 38 66841 191582 53090605
Angina pectoris 120.77 10.18 164 66715 28561 53253626
Oligohydramnios 120.52 10.18 82 66797 5994 53276193
Completed suicide 112.43 10.18 19 66860 138182 53144005
Drug interaction 108.95 10.18 553 66326 218776 53063411
Rheumatoid arthritis 105.72 10.18 144 66735 314387 52967800
Synovitis 104.76 10.18 8 66871 107885 53174302
Maternal exposure during pregnancy 103.67 10.18 33 66846 155606 53126581
Bradycardia 103.54 10.18 256 66623 70800 53211387
Syncope 100.53 10.18 339 66540 111654 53170533
Death 97.16 10.18 188 66691 357044 52925143
Drug hypersensitivity 94.71 10.18 116 66763 265126 53017061
Renal impairment 93.95 10.18 273 66606 83045 53199142
Blood pressure increased 93.35 10.18 386 66493 140093 53142094
Glossodynia 93.10 10.18 9 66870 100282 53181905
Hand deformity 92.74 10.18 3 66876 84846 53197341
Hypotension 92.16 10.18 589 66290 253487 53028700
Pain 91.86 10.18 403 66476 587995 52694192
Cardiac failure 88.03 10.18 272 66607 85572 53196615
Haematochezia 85.73 10.18 174 66705 42184 53240003
Lactic acidosis 85.06 10.18 161 66718 37092 53245095
Arthropathy 84.08 10.18 36 66843 141417 53140770
Dizziness 83.46 10.18 771 66108 371488 52910699
Swelling 81.23 10.18 72 66807 191033 53091154
Alopecia 80.18 10.18 106 66773 234477 53047710
Inappropriate antidiuretic hormone secretion 74.75 10.18 93 66786 14858 53267329
Injection site pain 73.80 10.18 25 66854 113366 53168821
Fall 73.69 10.18 729 66150 357711 52924476
Blood creatinine increased 67.87 10.18 243 66636 82419 53199768
Hypertensive crisis 67.40 10.18 87 66792 14419 53267768
Systemic lupus erythematosus 65.36 10.18 38 66841 125376 53156811
Orthostatic hypotension 64.74 10.18 126 66753 29627 53252560
Cough 63.09 10.18 543 66336 256350 53025837
Hypertension 62.60 10.18 490 66389 224941 53057246
Arterial occlusive disease 61.76 10.18 51 66828 4998 53277189
Product use issue 61.22 10.18 51 66828 139533 53142654
Sputum discoloured 58.95 10.18 81 66798 14258 53267929
Drug intolerance 58.55 10.18 105 66774 205388 53076799
Pericarditis 56.66 10.18 7 66872 64399 53217788
Hypoglycaemia 55.01 10.18 181 66698 58832 53223355
Abdominal discomfort 54.39 10.18 123 66756 220939 53061248
Product prescribing error 54.39 10.18 101 66778 22930 53259257
Contraindicated product administered 51.93 10.18 56 66823 135573 53146614
Anaemia 51.63 10.18 552 66327 276166 53006021
Atrial fibrillation 51.51 10.18 276 66603 111376 53170811
Anuria 50.73 10.18 70 66809 12370 53269817
Rubber sensitivity 50.56 10.18 31 66848 1894 53280293
Disorientation 50.28 10.18 135 66744 39224 53242963
Product monitoring error 49.99 10.18 36 66843 2881 53279306
Labile hypertension 49.58 10.18 20 66859 488 53281699
Joint swelling 48.91 10.18 142 66737 234496 53047691
Sinusitis 46.34 10.18 88 66791 168476 53113711
Neovascularisation 44.92 10.18 20 66859 627 53281560
Rash 44.18 10.18 353 66526 445838 52836349
Infection 43.01 10.18 95 66784 172110 53110077
Circulatory collapse 42.08 10.18 90 66789 22624 53259563
Vertigo 41.94 10.18 160 66719 55921 53226266
Dyspnoea 41.90 10.18 995 65884 585237 52696950
Hepatic enzyme increased 41.08 10.18 59 66820 126136 53156051
Cerebral infarction 40.92 10.18 93 66786 24351 53257836
Injection site erythema 40.82 10.18 23 66856 77226 53204961
Gamma-glutamyltransferase increased 39.78 10.18 112 66767 33443 53248744
Oedema peripheral 39.27 10.18 356 66523 170431 53111756
Peripheral swelling 39.21 10.18 130 66749 205978 53076209
Infusion related reaction 38.97 10.18 86 66793 155871 53126316
Basilar artery occlusion 38.96 10.18 12 66867 127 53282060
Haematoma 38.22 10.18 111 66768 33733 53248454
Gangrene 37.55 10.18 38 66841 4839 53277348
Wound 37.08 10.18 36 66843 91521 53190666
Psychomotor retardation 36.88 10.18 33 66846 3605 53278582
Aphasia 36.75 10.18 103 66776 30675 53251512
Off label use 36.65 10.18 397 66482 471815 52810372
Neurologic neglect syndrome 36.28 10.18 21 66858 1154 53281033
Androgenetic alopecia 36.18 10.18 12 66867 164 53282023
Rhabdomyolysis 35.93 10.18 129 66750 43794 53238393
Lung opacity 35.45 10.18 25 66854 1936 53280251
Pemphigoid 35.32 10.18 42 66837 6402 53275785
Forced expiratory volume decreased 34.99 10.18 39 66840 5546 53276641
Gastrointestinal disorder 34.62 10.18 37 66842 89967 53192220
Confusional state 34.13 10.18 383 66496 193838 53088349
Fibromyalgia 33.81 10.18 7 66872 44068 53238119
Diffuse alopecia 32.98 10.18 16 66863 612 53281575
Carotid artery thrombosis 32.77 10.18 20 66859 1212 53280975
Altered state of consciousness 32.54 10.18 86 66793 24750 53257437
Treatment failure 31.10 10.18 72 66807 128331 53153856
Renal failure 30.92 10.18 254 66625 118198 53163989
Duodenal ulcer perforation 30.52 10.18 4 66875 35179 53247008
Injection site reaction 30.41 10.18 13 66866 51153 53231034
Non-cardiogenic pulmonary oedema 30.16 10.18 15 66864 606 53281581
Occupational asthma 29.99 10.18 10 66869 139 53282048
Vasoplegia syndrome 29.95 10.18 19 66860 1233 53280954
Discomfort 29.74 10.18 46 66833 95426 53186761
Productive cough 29.46 10.18 145 66734 56584 53225603
Hospitalisation 28.66 10.18 28 66851 70984 53211203
No adverse event 28.58 10.18 7 66872 39258 53242929
Cholestatic liver injury 28.41 10.18 24 66855 2427 53279760
Total lung capacity decreased 27.77 10.18 19 66860 1401 53280786
Transaminases increased 27.69 10.18 92 66787 30040 53252147
Palpitations 27.54 10.18 221 66658 102127 53180060
Osteochondrosis 27.25 10.18 17 66862 1071 53281116
Chromaturia 27.05 10.18 61 66818 15889 53266298
Tinnitus 27.00 10.18 92 66787 30427 53251760
Adjustment disorder 26.87 10.18 21 66858 1902 53280285
Hypersensitivity 26.59 10.18 155 66724 210510 53071677
Helicobacter infection 26.50 10.18 8 66871 39061 53243126
Pulmonary hypoplasia 26.41 10.18 11 66868 292 53281895
Vestibular migraine 26.32 10.18 10 66869 207 53281980
Haematoma muscle 25.84 10.18 14 66865 676 53281511
Hypomagnesaemia 25.76 10.18 79 66800 24732 53257455
Disturbance in attention 25.62 10.18 98 66781 34285 53247902
Dehydration 25.56 10.18 323 66556 168087 53114100
Vertigo positional 25.53 10.18 24 66855 2792 53279395
Lichen planus 25.47 10.18 21 66858 2053 53280134
Mobility decreased 25.47 10.18 35 66844 76236 53205951
Blood hyposmosis 25.10 10.18 6 66873 21 53282166
Exposure during pregnancy 24.95 10.18 77 66802 124783 53157404
Tubulointerstitial nephritis 24.58 10.18 60 66819 16444 53265743
Skin haemorrhage 24.52 10.18 36 66843 6731 53275456
Arthralgia 24.46 10.18 396 66483 439387 52842800
Heart rate 24.36 10.18 7 66872 57 53282130
Carcinoid tumour of the caecum 24.28 10.18 6 66873 25 53282162
Oesophageal dilatation 24.15 10.18 11 66868 364 53281823
Intraventricular haemorrhage 23.88 10.18 20 66859 1998 53280189
Barotrauma 23.88 10.18 9 66870 182 53282005
Gastrointestinal tract adenoma 23.85 10.18 11 66868 375 53281812
Mental status changes 23.60 10.18 10 66869 39561 53242626
Therapeutic product effect incomplete 23.42 10.18 50 66829 91734 53190453
Hemiparesis 22.88 10.18 69 66810 21406 53260781
Myalgia 22.86 10.18 262 66617 133229 53148958
Product quality issue 22.66 10.18 9 66870 37014 53245173
Toxicity to various agents 22.47 10.18 172 66707 219426 53062761
Respiratory tract inflammation 22.31 10.18 12 66867 571 53281616
C-reactive protein abnormal 22.30 10.18 3 66876 25867 53256320
Hemiplegia 22.02 10.18 37 66842 7763 53274424
Ill-defined disorder 21.74 10.18 18 66861 49426 53232761
Purpura senile 21.59 10.18 12 66867 610 53281577
Internal haemorrhage 21.56 10.18 28 66851 4668 53277519
Interstitial lung disease 21.23 10.18 136 66743 58486 53223701
Hypokalaemia 21.05 10.18 199 66680 96318 53185869
Waist circumference increased 21.04 10.18 13 66866 805 53281382
Prerenal failure 21.03 10.18 17 66862 1617 53280570
Occult blood 20.85 10.18 15 66864 1199 53280988
Injection site swelling 20.70 10.18 14 66865 42614 53239573
International normalised ratio increased 20.61 10.18 116 66763 47645 53234542
Cerebellar syndrome 20.58 10.18 24 66855 3583 53278604
Extrapyramidal disorder 20.55 10.18 47 66832 12355 53269832
Arrhythmia 20.53 10.18 96 66783 36683 53245504
Decreased appetite 20.51 10.18 381 66498 214593 53067594
Abortion spontaneous 20.48 10.18 17 66862 46618 53235569
Therapy non-responder 20.25 10.18 19 66860 49101 53233086
Multiple sclerosis relapse 20.13 10.18 16 66863 44837 53237350
Shock haemorrhagic 20.11 10.18 39 66840 9144 53273043
Cornea verticillata 19.97 10.18 6 66873 58 53282129
Thyroid stimulating immunoglobulin increased 19.86 10.18 7 66872 116 53282071
Intravascular haemolysis 19.78 10.18 9 66870 297 53281890
Putamen haemorrhage 19.73 10.18 8 66871 198 53281989
Cerebral haemorrhage 19.55 10.18 82 66797 29914 53252273
Blood creatine phosphokinase increased 19.49 10.18 80 66799 28905 53253282
Multiple sclerosis 19.46 10.18 5 66874 27148 53255039
Intentional overdose 19.42 10.18 34 66845 67171 53215016
Mental status changes postoperative 19.39 10.18 8 66871 207 53281980
Thirst 19.35 10.18 44 66835 11522 53270665
Melaena 19.27 10.18 80 66799 29049 53253138
Sinus arrest 19.23 10.18 17 66862 1827 53280360
Malaise 19.13 10.18 585 66294 357032 52925155
Dyspnoea at rest 19.04 10.18 24 66855 3883 53278304
Systemic infection 18.91 10.18 18 66861 2127 53280060
Atrioventricular block complete 18.73 10.18 35 66844 7980 53274207
Sensitivity to weather change 18.58 10.18 30 66849 6092 53276095
Adverse drug reaction 18.52 10.18 24 66855 53601 53228586
Injection site pruritus 18.46 10.18 15 66864 41574 53240613
Renal aplasia 18.36 10.18 8 66871 238 53281949
Therapeutic product effect decreased 18.32 10.18 88 66791 125567 53156620
Confusion postoperative 18.17 10.18 8 66871 244 53281943
Impaired healing 18.08 10.18 33 66846 64172 53218015
Plasma cell myeloma 18.05 10.18 20 66859 47854 53234333
Acute myocardial infarction 18.00 10.18 86 66793 33149 53249038
Hypouricaemia 17.74 10.18 7 66872 161 53282026
Device issue 17.55 10.18 3 66876 21655 53260532
Injection site bruising 17.44 10.18 13 66866 37633 53244554
Pneumobilia 17.42 10.18 7 66872 169 53282018
Histamine intolerance 17.37 10.18 5 66874 41 53282146
Psoriatic arthropathy 17.23 10.18 21 66858 48169 53234018
Painful respiration 17.22 10.18 19 66860 2671 53279516
Blood uric acid increased 17.13 10.18 24 66855 4300 53277887
Paradoxical drug reaction 17.13 10.18 21 66858 3304 53278883
Glomerulonephritis chronic 17.12 10.18 7 66872 177 53282010
Therapeutic response changed 17.09 10.18 12 66867 923 53281264
Stenosis 16.69 10.18 13 66866 1172 53281015
Renal impairment neonatal 16.67 10.18 5 66874 48 53282139
Iron deficiency 16.62 10.18 29 66850 6271 53275916
Motor dysfunction 16.62 10.18 34 66845 8284 53273903
Asthenia 16.53 10.18 555 66324 343035 52939152
Iron deficiency anaemia 16.43 10.18 56 66823 18524 53263663
Female sterilisation 16.41 10.18 10 66869 604 53281583
Disease progression 16.28 10.18 69 66810 101851 53180336
Renal tubular disorder 16.26 10.18 19 66860 2844 53279343
Hepatic function abnormal 16.18 10.18 90 66789 36809 53245378
Intentional product misuse 16.15 10.18 23 66856 49369 53232818
Full blood count decreased 16.15 10.18 5 66874 24024 53258163
Psoas abscess 16.07 10.18 9 66870 464 53281723
Dermatosis 16.04 10.18 8 66871 325 53281862
Wrong strength 15.98 10.18 5 66874 56 53282131
Tarsal tunnel syndrome 15.96 10.18 10 66869 635 53281552
Bronchopulmonary aspergillosis allergic 15.87 10.18 13 66866 1259 53280928
Treatment noncompliance 15.84 10.18 11 66868 33024 53249163
Neuropathy peripheral 15.79 10.18 71 66808 103116 53179071
Accidental exposure to product 15.78 10.18 5 66874 23669 53258518
Hypoaesthesia 15.64 10.18 100 66779 132895 53149292
Spider naevus 15.62 10.18 6 66873 128 53282059
Labelled drug-drug interaction medication error 15.57 10.18 39 66840 10860 53271327
Prothrombin time shortened 15.50 10.18 15 66864 1809 53280378
Loss of personal independence in daily activities 15.45 10.18 41 66838 69774 53212413
Chest wall mass 15.44 10.18 5 66874 63 53282124
Hypoosmolar state 15.44 10.18 7 66872 229 53281958
Tenderness 15.41 10.18 3 66876 19727 53262460
Drug ineffective for unapproved indication 15.39 10.18 59 66820 20661 53261526
Gastrointestinal haemorrhage 15.28 10.18 161 66718 80169 53202018
Unevaluable event 15.26 10.18 24 66855 49474 53232713
Clostridium difficile infection 15.17 10.18 8 66871 27885 53254302
Cor pulmonale acute 14.95 10.18 8 66871 377 53281810
Urinary retention 14.94 10.18 73 66806 28393 53253794
Blood pressure inadequately controlled 14.81 10.18 24 66855 4887 53277300
Agranulocytosis 14.76 10.18 64 66815 23685 53258502
Ventricular extrasystoles 14.75 10.18 40 66839 11684 53270503
Vestibular disorder 14.70 10.18 13 66866 1398 53280789
Cerebral haematoma 14.67 10.18 20 66859 3494 53278693
Staphylococcal infection 14.65 10.18 16 66863 38532 53243655
Urogenital haemorrhage 14.62 10.18 7 66872 260 53281927
Glomerular filtration rate decreased 14.53 10.18 42 66837 12725 53269462
Blood pressure measurement 14.52 10.18 7 66872 264 53281923
Potentiating drug interaction 14.52 10.18 22 66857 4231 53277956
Gastroenteritis 14.40 10.18 67 66812 25549 53256638
Subdural haematoma 14.35 10.18 44 66835 13769 53268418
Aortic dissection 14.35 10.18 14 66865 1706 53280481
Walking disability 14.34 10.18 13 66866 1444 53280743
Binocular eye movement disorder 14.33 10.18 4 66875 29 53282158
Sinonasal obstruction 14.31 10.18 6 66873 162 53282025
Brain stem stroke 14.28 10.18 7 66872 274 53281913
Wrong technique in product usage process 14.26 10.18 34 66845 59998 53222189
Blood sodium decreased 14.14 10.18 62 66817 23054 53259133
Lip infection 14.12 10.18 5 66874 84 53282103
Obstructive airways disorder 14.09 10.18 51 66828 17378 53264809
Bradyarrhythmia 14.08 10.18 15 66864 2028 53280159
Glossitis 14.06 10.18 18 66861 2958 53279229
Visual acuity reduced transiently 13.91 10.18 6 66873 174 53282013
C-reactive protein increased 13.83 10.18 138 66741 67748 53214439
Microcytic anaemia 13.73 10.18 19 66860 3366 53278821
Ultrasound kidney abnormal 13.67 10.18 4 66875 35 53282152
Hyperuricaemia 13.62 10.18 24 66855 5232 53276955
Irritable bowel syndrome 13.60 10.18 21 66858 43611 53238576
Thalamus haemorrhage 13.57 10.18 9 66870 630 53281557
Sepsis 13.46 10.18 118 66761 146311 53135876
Diabetic ketoacidosis 13.41 10.18 55 66824 19860 53262327
Blister 13.41 10.18 52 66827 78701 53203486
Musculoskeletal stiffness 13.39 10.18 95 66784 123273 53158914
Breast discomfort 13.36 10.18 8 66871 468 53281719
Cardiorenal syndrome 13.32 10.18 9 66870 650 53281537
Flatulence 13.24 10.18 76 66803 31441 53250746
Pain in jaw 13.24 10.18 19 66860 40650 53241537
Cardiac murmur functional 13.19 10.18 4 66875 40 53282147
Metastases to fallopian tube 13.19 10.18 4 66875 40 53282147
Sensory loss 13.14 10.18 30 66849 7875 53274312
Language disorder 13.11 10.18 14 66865 1897 53280290
Merycism 13.08 10.18 6 66873 202 53281985
Gastroenteritis viral 13.05 10.18 4 66875 19341 53262846
Retroperitoneal haematoma 13.00 10.18 17 66862 2853 53279334
Hypochloraemia 12.90 10.18 14 66865 1932 53280255
Drug metabolising enzyme decreased 12.90 10.18 3 66876 9 53282178
Eosinophilia 12.88 10.18 57 66822 21278 53260909
Blood urea increased 12.87 10.18 66 66813 26165 53256022
Spinal osteoarthritis 12.80 10.18 45 66834 15112 53267075
Device capturing issue 12.77 10.18 4 66875 45 53282142
Retroperitoneal fibrosis 12.75 10.18 7 66872 347 53281840
Urticaria 12.71 10.18 109 66770 135776 53146411
Polyneuropathy 12.69 10.18 41 66838 13192 53268995
Therapy cessation 12.57 10.18 10 66869 28015 53254172
Eczema nummular 12.55 10.18 6 66873 222 53281965
Device dislocation 12.50 10.18 7 66872 23590 53258597
White blood cell count decreased 12.48 10.18 98 66781 124377 53157810
Subarachnoid haemorrhage 12.47 10.18 38 66841 11855 53270332
Blood sodium abnormal 12.46 10.18 9 66870 724 53281463
Brain natriuretic peptide abnormal 12.38 10.18 7 66872 368 53281819
Endometrial cancer 12.37 10.18 17 66862 2991 53279196
Granulomatosis with polyangiitis 12.37 10.18 14 66865 2025 53280162
Ischaemic stroke 12.36 10.18 50 66829 17943 53264244
Blood pressure systolic increased 12.36 10.18 81 66798 35096 53247091
Proteinuria 12.25 10.18 50 66829 18018 53264169
Neutropenia 12.22 10.18 134 66745 159051 53123136
Personality disorder 12.20 10.18 20 66859 4111 53278076
Miosis 12.12 10.18 27 66852 6975 53275212
Body temperature increased 12.04 10.18 14 66865 32785 53249402
Pregnancy 12.00 10.18 13 66866 31428 53250759
Aplasia pure red cell 11.92 10.18 21 66858 4575 53277612
Drug dependence 11.92 10.18 6 66873 21466 53260721
Pharyngeal enanthema 11.91 10.18 4 66875 57 53282130
Laboratory test abnormal 11.87 10.18 8 66871 24401 53257786
Depression 11.81 10.18 160 66719 182892 53099295
Muscular weakness 11.80 10.18 185 66694 100807 53181380
Thrombosis 11.78 10.18 38 66841 60755 53221432
Vital capacity decreased 11.69 10.18 10 66869 1029 53281158
Adverse event 11.65 10.18 21 66858 41040 53241147
Upper gastrointestinal haemorrhage 11.63 10.18 48 66831 17382 53264805
Anaemia folate deficiency 11.63 10.18 6 66873 262 53281925
Seizure 11.62 10.18 105 66774 129404 53152783
Drug therapeutic incompatibility 11.60 10.18 4 66875 62 53282125
Leishmaniasis 11.60 10.18 4 66875 62 53282125
Nocturia 11.59 10.18 28 66851 7622 53274565
Cystitis escherichia 11.58 10.18 7 66872 417 53281770
Neonatal hypotension 11.56 10.18 5 66874 146 53282041
Complication associated with device 11.54 10.18 3 66876 16162 53266025
Hallucinations, mixed 11.33 10.18 20 66859 4366 53277821
Leiomyoma 11.28 10.18 7 66872 437 53281750
Reticulocyte count increased 11.25 10.18 9 66870 843 53281344
Product impurity 11.20 10.18 4 66875 69 53282118
Electrolyte imbalance 11.06 10.18 50 66829 18834 53263353
Anti-thyroid antibody positive 11.04 10.18 7 66872 454 53281733
Polyuria 10.98 10.18 28 66851 7883 53274304
Presyncope 10.89 10.18 63 66816 26131 53256056
Musculoskeletal pain 10.87 10.18 143 66736 75057 53207130
Resorption bone increased 10.87 10.18 10 66869 1132 53281055
Osmotic demyelination syndrome 10.83 10.18 8 66871 666 53281521
Affect lability 10.82 10.18 31 66848 9344 53272843
Febrile neutropenia 10.81 10.18 82 66797 104854 53177333
Haematemesis 10.81 10.18 71 66808 30786 53251401
Gastritis bacterial 10.80 10.18 4 66875 77 53282110
Lordosis 10.72 10.18 6 66873 309 53281878
Delayed fontanelle closure 10.72 10.18 3 66876 22 53282165
Foetal malformation 10.69 10.18 5 66874 176 53282011
Transient ischaemic attack 10.63 10.18 79 66800 35646 53246541
Knee arthroplasty 10.62 10.18 16 66863 33553 53248634
Chronic obstructive pulmonary disease 10.60 10.18 40 66839 61033 53221154
Incarcerated incisional hernia 10.60 10.18 3 66876 23 53282164
Product used for unknown indication 10.56 10.18 8 66871 692 53281495
Chemotherapeutic drug level increased 10.51 10.18 5 66874 183 53282004
Microangiopathy 10.44 10.18 9 66870 935 53281252
Stasis dermatitis 10.44 10.18 8 66871 704 53281483
Gastric ulcer haemorrhage 10.42 10.18 21 66858 5061 53277126
Hyperthyroidism 10.35 10.18 38 66841 13035 53269152
COVID-19 10.35 10.18 19 66860 36869 53245318
Cystitis 10.30 10.18 97 66782 46891 53235296
Renal function test abnormal 10.23 10.18 16 66863 3161 53279026
Injection site rash 10.19 10.18 4 66875 16575 53265612

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
General physical health deterioration 215.06 10.63 529 51338 114730 32346929
Death 155.24 10.63 232 51635 382285 32079374
Hyperkalaemia 152.68 10.63 341 51526 69409 32392250
Acute kidney injury 152.30 10.63 891 50976 292577 32169082
Product monitoring error 149.94 10.63 76 51791 2498 32459161
Completed suicide 122.57 10.63 6 51861 92511 32369148
Haematochezia 116.97 10.63 218 51649 38990 32422669
Product prescribing error 90.32 10.63 133 51734 19584 32442075
Product dose omission issue 84.63 10.63 29 51838 102546 32359113
Toxicity to various agents 81.01 10.63 99 51768 177942 32283717
Labelled drug-drug interaction medication error 69.17 10.63 92 51775 12321 32449338
Bradycardia 63.48 10.63 254 51613 71308 32390351
Hypertension 56.70 10.63 382 51485 131368 32330291
Angina pectoris 56.06 10.63 142 51725 31284 32430375
Dizziness 56.04 10.63 545 51322 209073 32252586
Neutropenia 53.80 10.63 90 51777 142085 32319574
Drug abuse 53.14 10.63 31 51836 80212 32381447
Renal impairment 51.81 10.63 286 51581 91686 32369973
Drug ineffective 50.85 10.63 381 51486 383096 32078563
Pulmonary hypoplasia 47.74 10.63 20 51847 419 32461240
Cardiac failure 42.56 10.63 271 51596 91402 32370257
Blood cholesterol 40.48 10.63 14 51853 169 32461490
Lymphocyte count abnormal 39.15 10.63 20 51847 668 32460991
Interstitial lung disease 37.84 10.63 204 51663 64797 32396862
Gastrointestinal angiodysplasia 37.21 10.63 19 51848 634 32461025
Plasma cell myeloma 37.09 10.63 23 51844 57591 32404068
Electrolyte imbalance 35.53 10.63 68 51799 12394 32449265
Off label use 35.20 10.63 316 51551 306004 32155655
Neuropathy peripheral 34.74 10.63 43 51824 76939 32384720
Disease progression 33.75 10.63 54 51813 86808 32374851
Sepsis 33.52 10.63 135 51732 158699 32302960
Nipple inflammation 33.38 10.63 10 51857 73 32461586
Cerebral infarction 32.94 10.63 108 51759 27506 32434153
Vitamin D deficiency 32.74 10.63 44 51823 5950 32455709
Agitation 32.69 10.63 26 51841 57210 32404449
Renal artery thrombosis 32.66 10.63 14 51853 311 32461348
Hospitalisation 32.29 10.63 19 51848 48952 32412707
Seizure 32.11 10.63 74 51793 103780 32357879
Pemphigoid 31.76 10.63 52 51815 8384 32453275
Anencephaly 31.21 10.63 11 51856 141 32461518
C-reactive protein decreased 31.10 10.63 24 51843 1672 32459987
Blood pressure increased 31.09 10.63 225 51642 79129 32382530
Abdominal pain lower 31.01 10.63 55 51812 9458 32452201
Multiple drug therapy 30.78 10.63 14 51853 360 32461299
Blood creatinine increased 30.73 10.63 260 51607 95872 32365787
Cardiac arrest 30.70 10.63 68 51799 96708 32364951
Presyncope 30.66 10.63 78 51789 17223 32444436
Dyspnoea 30.54 10.63 774 51093 361271 32100388
Febrile neutropenia 30.31 10.63 94 51773 119472 32342187
Myalgia 29.94 10.63 227 51640 81003 32380656
Intestinal haemorrhage 28.63 10.63 31 51836 3348 32458311
Patient dissatisfaction with treatment 27.73 10.63 9 51858 88 32461571
Drug interaction 27.60 10.63 495 51372 217690 32243969
Pneumonia 27.28 10.63 401 51466 354851 32106808
Oedema peripheral 26.75 10.63 289 51578 113802 32347857
Blood pressure inadequately controlled 26.69 10.63 27 51840 2695 32458964
Jaundice 26.17 10.63 116 51751 34042 32427617
Respiratory arrest 25.93 10.63 7 51860 28901 32432758
Colitis 25.79 10.63 115 51752 33836 32427823
Peripheral arterial occlusive disease 25.40 10.63 38 51829 5671 32455988
Mental status changes 25.10 10.63 15 51852 38322 32423337
Hypertensive crisis 25.00 10.63 48 51819 8769 32452890
Contraindicated product administered 24.94 10.63 77 51790 18999 32442660
Blood glucose fluctuation 24.33 10.63 31 51836 3978 32457681
Arrhythmia 24.17 10.63 116 51751 35187 32426472
Hyperuricaemia 23.92 10.63 45 51822 8096 32453563
Intentional product misuse 23.75 10.63 14 51853 36037 32425622
Nipple disorder 23.72 10.63 10 51857 213 32461446
Hypoxia 23.64 10.63 29 51838 52103 32409556
Lactic acidosis 22.82 10.63 110 51757 33426 32428233
Haematoma 22.61 10.63 91 51776 25593 32436066
Renal artery stenosis 22.37 10.63 21 51846 1912 32459747
Joint contracture 22.28 10.63 21 51846 1922 32459737
Treatment failure 22.10 10.63 18 51849 39145 32422514
Lung hernia 20.91 10.63 7 51860 76 32461583
Acute cutaneous lupus erythematosus 20.66 10.63 7 51860 79 32461580
Aortic valve incompetence 20.39 10.63 33 51834 5270 32456389
Gastrointestinal ischaemia 20.20 10.63 9 51858 220 32461439
White blood cell count decreased 20.18 10.63 76 51791 91122 32370537
Hallucination 20.16 10.63 33 51834 52586 32409073
Atrioventricular block second degree 20.00 10.63 26 51841 3404 32458255
Breast pain 19.96 10.63 17 51850 1362 32460297
Hemiataxia 19.77 10.63 6 51861 46 32461613
Nervous system neoplasm 19.72 10.63 8 51859 154 32461505
Sedation 19.70 10.63 3 51864 18523 32443136
Mucosal haemorrhage 19.58 10.63 18 51849 1596 32460063
Gamma-glutamyltransferase increased 19.54 10.63 99 51768 30683 32430976
Adrenal insufficiency 19.21 10.63 52 51815 11916 32449743
Total cholesterol/HDL ratio increased 19.08 10.63 8 51859 168 32461491
Urinary hesitation 19.00 10.63 21 51846 2320 32459339
Oral lichen planus 18.74 10.63 8 51859 176 32461483
Drug dependence 18.73 10.63 7 51860 23477 32438182
Food aversion 18.47 10.63 10 51857 377 32461282
Blood creatine phosphokinase increased 18.41 10.63 130 51737 45346 32416313
Diabetes mellitus inadequate control 18.39 10.63 56 51811 13712 32447947
Vasculitic rash 18.36 10.63 14 51853 958 32460701
Anxiety disorder due to a general medical condition 18.11 10.63 4 51863 6 32461653
Sinusitis 18.03 10.63 19 51848 36541 32425118
Eczema eyelids 17.97 10.63 5 51862 27 32461632
Rhabdomyolysis 17.94 10.63 175 51692 67090 32394569
Blood glucose abnormal 17.82 10.63 32 51835 5556 32456103
Therapeutic product effect decreased 17.82 10.63 14 51853 31003 32430656
No adverse event 17.72 10.63 5 51862 20048 32441611
Hypochromic anaemia 17.68 10.63 13 51854 842 32460817
Tonsillar ulcer 17.61 10.63 8 51859 205 32461454
Hypotension 17.55 10.63 460 51407 215650 32246009
Full blood count decreased 17.53 10.63 3 51864 17007 32444652
Renal artery stent placement 17.39 10.63 4 51863 8 32461651
Renal artery angioplasty 17.39 10.63 4 51863 8 32461651
Duodenal ulcer 17.36 10.63 46 51821 10409 32451250
Hyponatraemia 17.10 10.63 188 51679 74325 32387334
Ventricular extrasystoles 17.09 10.63 50 51817 11976 32449683
Congenital renal disorder 17.09 10.63 6 51861 76 32461583
Unevaluable event 17.08 10.63 17 51850 33569 32428090
Macular ischaemia 16.94 10.63 6 51861 78 32461581
Drug resistance 16.47 10.63 8 51859 22957 32438702
Paresis cranial nerve 16.41 10.63 6 51861 86 32461573
Congenital muscle absence 16.40 10.63 5 51862 39 32461620
Congenital vas deferens absence 16.40 10.63 5 51862 39 32461620
Device lead damage 16.33 10.63 3 51864 0 32461659
Choroidal detachment 16.27 10.63 9 51858 354 32461305
Post concussion syndrome 16.16 10.63 6 51861 90 32461569
Incarcerated inguinal hernia 16.16 10.63 6 51861 90 32461569
Therapy non-responder 16.07 10.63 17 51850 32637 32429022
Product use in unapproved indication 16.02 10.63 78 51789 87126 32374533
Blood pressure fluctuation 15.89 10.63 69 51798 20066 32441593
Xanthopsia 15.87 10.63 7 51860 167 32461492
Syncope 15.75 10.63 216 51651 89908 32371751
Basilar artery thrombosis 15.39 10.63 7 51860 180 32461479
Pain 15.29 10.63 209 51658 187347 32274312
Hepatic ischaemia 15.29 10.63 9 51858 399 32461260
Diabetic nephropathy 15.21 10.63 18 51849 2141 32459518
Coronary artery stenosis 15.17 10.63 42 51825 9751 32451908
Prolonged expiration 15.04 10.63 7 51860 190 32461469
Aortic valve stenosis 14.99 10.63 18 51849 2174 32459485
Shock hypoglycaemic 14.96 10.63 6 51861 112 32461547
Renal failure 14.87 10.63 299 51568 134179 32327480
Respiratory failure 14.83 10.63 105 51762 107077 32354582
Skull malformation 14.82 10.63 9 51858 423 32461236
Neurotoxicity 14.80 10.63 3 51864 15067 32446592
Costovertebral angle tenderness 14.71 10.63 5 51862 57 32461602
Pancreatitis acute 14.69 10.63 84 51783 27251 32434408
Hepatic function abnormal 14.69 10.63 122 51745 44718 32416941
Muscle rupture 14.67 10.63 18 51849 2224 32459435
Retinal artery occlusion 14.65 10.63 16 51851 1745 32459914
Cerebral haematoma 14.64 10.63 27 51840 4784 32456875
Orthostatic hypotension 14.57 10.63 80 51787 25570 32436089
Haematuria 14.49 10.63 129 51738 48232 32413427
Neuroleptic malignant syndrome 14.32 10.63 5 51862 17490 32444169
Mixed liver injury 14.18 10.63 19 51848 2561 32459098
Coronavirus infection 14.13 10.63 23 51844 3689 32457970
Primary hyperaldosteronism 14.12 10.63 5 51862 65 32461594
Bronchopulmonary aspergillosis allergic 14.01 10.63 10 51857 618 32461041
Unresponsive to stimuli 14.01 10.63 14 51853 27595 32434064
Cytomegalovirus infection 14.00 10.63 12 51855 25452 32436207
Oligohydramnios 13.86 10.63 8 51859 342 32461317
Pterygium 13.85 10.63 6 51861 137 32461522
Product use issue 13.71 10.63 41 51826 52736 32408923
Glycosylated haemoglobin increased 13.64 10.63 42 51825 10347 32451312
pH body fluid increased 13.62 10.63 4 51863 27 32461632
Generalised tonic-clonic seizure 13.61 10.63 8 51859 20631 32441028
Systemic infection 13.44 10.63 17 51850 2166 32459493
Pallor 13.43 10.63 72 51795 22809 32438850
Supine hypertension 13.42 10.63 8 51859 363 32461296
Hypozincaemia 13.39 10.63 3 51864 5 32461654
Desmoplastic melanoma 13.38 10.63 4 51863 29 32461630
Lymphocyte count 13.35 10.63 5 51862 77 32461582
Product quality issue 13.34 10.63 7 51860 19226 32442433
Alopecia universalis 13.29 10.63 5 51862 78 32461581
Papillary renal cell carcinoma 13.27 10.63 6 51861 152 32461507
Urogenital haemorrhage 13.19 10.63 9 51858 517 32461142
Basal ganglia haemorrhage 13.12 10.63 11 51856 863 32460796
Periorbital discomfort 13.03 10.63 4 51863 32 32461627
Eosinophilic pneumonia 12.86 10.63 20 51847 3086 32458573
Brain stem infarction 12.83 10.63 13 51854 1300 32460359
Vertebral artery stenosis 12.82 10.63 6 51861 165 32461494
Cranial sutures widening 12.74 10.63 5 51862 88 32461571
Rhinalgia 12.58 10.63 8 51859 408 32461251
Idiopathic pulmonary fibrosis 12.55 10.63 24 51843 4371 32457288
Mechanical urticaria 12.53 10.63 5 51862 92 32461567
Cardiovascular insufficiency 12.48 10.63 14 51853 1572 32460087
Oliguria 12.44 10.63 35 51832 8199 32453460
Neurologic neglect syndrome 12.43 10.63 6 51861 177 32461482
Prothrombin time shortened 12.41 10.63 14 51853 1582 32460077
Fluid overload 12.39 10.63 8 51859 19613 32442046
Renal ischaemia 12.29 10.63 9 51858 579 32461080
Gastrointestinal disorder 12.27 10.63 88 51779 30843 32430816
Inguinal hernia 12.21 10.63 34 51833 7918 32453741
Renovascular hypertension 12.18 10.63 3 51864 9 32461650
Thrombocytopenia 12.17 10.63 165 51702 148134 32313525
Subileus 12.11 10.63 20 51847 3248 32458411
Bradyarrhythmia 12.05 10.63 16 51851 2138 32459521
Aortic valve disease mixed 11.97 10.63 5 51862 104 32461555
Mesenteric artery thrombosis 11.86 10.63 8 51859 451 32461208
Candida infection 11.83 10.63 6 51861 16797 32444862
Respiratory distress 11.80 10.63 24 51843 35222 32426437
Wrong dose 11.78 10.63 8 51859 456 32461203
Laboratory test abnormal 11.76 10.63 8 51859 19079 32442580
Lip ulceration 11.76 10.63 10 51857 800 32460859
Renin increased 11.75 10.63 5 51862 109 32461550
Vasoplegia syndrome 11.73 10.63 13 51854 1441 32460218
Fracture 11.71 10.63 30 51837 6649 32455010
Anti-erythropoietin antibody negative 11.70 10.63 6 51861 202 32461457
Atypical fibroxanthoma 11.65 10.63 6 51861 204 32461455
Conduction disorder 11.47 10.63 15 51852 1975 32459684
Bacteraemia 11.40 10.63 7 51860 17626 32444033
Vascular stent thrombosis 11.40 10.63 17 51850 2530 32459129
Stomal hernia 11.12 10.63 5 51862 125 32461534
Palmar-plantar erythrodysaesthesia syndrome 10.96 10.63 52 51815 15697 32445962
Fatigue 10.95 10.63 453 51414 350248 32111411
Hepatitis acute 10.88 10.63 31 51836 7314 32454345
Blood growth hormone increased 10.85 10.63 6 51861 236 32461423
Eczema 10.82 10.63 50 51817 14930 32446729
Urinary tract infection 10.80 10.63 79 51788 79992 32381667
Urethral disorder 10.78 10.63 4 51863 60 32461599

Pharmacologic Action:

SourceCodeDescription
FDA MoA N0000000070 Angiotensin 2 Receptor Antagonists
FDA EPC N0000175561 Angiotensin 2 Receptor Blocker
MeSH PA D047228 Angiotensin II Type 1 Receptor Blockers
MeSH PA D057911 Angiotensin Receptor Antagonists
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Chronic heart failure indication 48447003
Atrial fibrillation off-label use 49436004 DOID:0060224
Diabetic renal disease off-label use 127013003
Diastolic heart failure off-label use 418304008 DOID:9775
Nondiabetic Proteinuric Nephropathy off-label use
Anuria contraindication 2472002 DOID:2983
Hypercholesterolemia contraindication 13644009
Hyperkalemia contraindication 14140009
Secondary angle-closure glaucoma contraindication 21571006
Hypovolemia contraindication 28560003
Dehydration contraindication 34095006
Hyperuricemia contraindication 35885006 DOID:1920
Hypokalemia contraindication 43339004
Low blood pressure contraindication 45007003
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Sympathectomy contraindication 57071006
Hypercalcemia contraindication 66931009 DOID:12678
Hyperparathyroidism contraindication 66999008 DOID:13543
Hypochloremic alkalosis contraindication 70134007
Hepatic coma contraindication 72836002 DOID:12550
Diabetes mellitus contraindication 73211009 DOID:9351
Oliguria contraindication 83128009
Hyponatremia contraindication 89627008
Gout contraindication 90560007 DOID:13189
Hypomagnesemia contraindication 190855004
Acute pancreatitis contraindication 197456007 DOID:2913
Impaired renal function disorder contraindication 197663003
Disease of liver contraindication 235856003 DOID:409
Neonatal hyperbilirubinemia contraindication 281610001
Pregnancy, function contraindication 289908002
Renal artery stenosis contraindication 302233006
Surgical procedure contraindication 387713003
Azotemia contraindication 445009001

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.25 acidic
pKa2 3.2 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Type-1 angiotensin II receptor GPCR ANTAGONIST IC50 9.16 CHEMBL CHEMBL
Sodium-dependent noradrenaline transporter Transporter Ki 5.52 CHEMBL
Alpha-2B adrenergic receptor GPCR Ki 5.76 CHEMBL
Beta-3 adrenergic receptor GPCR Ki 5.49 CHEMBL
Adenosine receptor A3 GPCR Ki 6.16 CHEMBL
Cytochrome P450 2C9 Enzyme IC50 5.52 CHEMBL
Epidermal growth factor receptor Kinase IC50 5.48 CHEMBL
Receptor tyrosine-protein kinase erbB-2 Kinase IC50 5.23 CHEMBL
Thromboxane-A synthase Enzyme IC50 5.51 CHEMBL
DNA polymerase kappa Enzyme IC50 5.25 CHEMBL
DNA polymerase iota Enzyme IC50 5.21 CHEMBL
Cytochrome P450 3A4 Enzyme IC50 5.05 CHEMBL
DNA polymerase eta Enzyme IC50 4.95 CHEMBL
Type-1 angiotensin II receptor GPCR IC50 6.96 CHEMBL
Cruzipain Enzyme IC50 4.38 CHEMBL
Type-1 angiotensin II receptor GPCR Ki 9.19 CHEMBL

External reference:

IDSource
4021148 VUID
N0000179517 NUI
D00522 KEGG_DRUG
139481-59-7 SECONDARY_CAS_RN
C0527379 UMLSCUI
CHEBI:3348 CHEBI
CHEBI:149509 CHEBI
CHEMBL1014 ChEMBL_ID
DB00796 DRUGBANK_ID
C077793 MESH_SUPPLEMENTAL_RECORD_UI
8352 IUPHAR_LIGAND_ID
C081643 MESH_SUPPLEMENTAL_RECORD_UI
587 IUPHAR_LIGAND_ID
7239 INN_ID
R85M2X0D68 UNII
S8Q36MD2XX UNII
2540 PUBCHEM_CID
2541 PUBCHEM_CID
DB13919 DRUGBANK_ID
135481 RXNORM
188909 MMSL
7490 MMSL
d04322 MMSL
007275 NDDF
007276 NDDF
108587008 SNOMEDCT_US
372512008 SNOMEDCT_US
386878000 SNOMEDCT_US
4021148 VANDF
4021151 VANDF
C0717550 UMLSCUI
CHEMBL1016 ChEMBL_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Candesartan Cilexetil and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0378-3001 TABLET 16 mg ORAL ANDA 21 sections
Candesartan Cilexetil and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0378-3002 TABLET 32 mg ORAL ANDA 21 sections
Candesartan Cilexetil and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0378-3003 TABLET 32 mg ORAL ANDA 21 sections
candesartan cilexetil HUMAN PRESCRIPTION DRUG LABEL 1 0378-3224 TABLET 4 mg ORAL ANDA 27 sections
candesartan cilexetil HUMAN PRESCRIPTION DRUG LABEL 1 0378-3225 TABLET 8 mg ORAL ANDA 27 sections
candesartan cilexetil HUMAN PRESCRIPTION DRUG LABEL 1 0378-3231 TABLET 16 mg ORAL ANDA 27 sections
candesartan cilexetil HUMAN PRESCRIPTION DRUG LABEL 1 0378-3232 TABLET 32 mg ORAL ANDA 27 sections
Candesartan HUMAN PRESCRIPTION DRUG LABEL 1 0904-7034 TABLET 32 mg ORAL ANDA 28 sections
Candesartan Human Prescription Drug Label 1 33342-114 TABLET 4 mg ORAL ANDA 28 sections
Candesartan Human Prescription Drug Label 1 33342-115 TABLET 8 mg ORAL ANDA 28 sections
Candesartan Human Prescription Drug Label 1 33342-116 TABLET 16 mg ORAL ANDA 28 sections
Candesartan Human Prescription Drug Label 1 33342-117 TABLET 32 mg ORAL ANDA 28 sections
Candesartan Cilexetil and Hydrochlorothiazide Human Prescription Drug Label 2 33342-131 TABLET 16 mg ORAL ANDA 19 sections
Candesartan Cilexetil and Hydrochlorothiazide Human Prescription Drug Label 2 33342-132 TABLET 32 mg ORAL ANDA 19 sections
Candesartan Cilexetil and Hydrochlorothiazide Human Prescription Drug Label 2 33342-133 TABLET 32 mg ORAL ANDA 19 sections
candesartan cilexetil and hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 43547-459 TABLET 16 mg ORAL ANDA 22 sections
candesartan cilexetil and hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 43547-460 TABLET 32 mg ORAL ANDA 22 sections
candesartan cilexetil and hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 43547-461 TABLET 32 mg ORAL ANDA 22 sections
CANDESARTAN CILEXETIL Human Prescription Drug Label 1 46708-060 TABLET 32 mg ORAL ANDA 27 sections
CANDESARTAN CILEXETIL Human Prescription Drug Label 1 46708-341 TABLET 4 mg ORAL ANDA 28 sections
CANDESARTAN CILEXETIL Human Prescription Drug Label 1 46708-342 TABLET 8 mg ORAL ANDA 28 sections
CANDESARTAN CILEXETIL Human Prescription Drug Label 1 46708-343 TABLET 16 mg ORAL ANDA 28 sections
Candesartan cilexetil HUMAN PRESCRIPTION DRUG LABEL 1 49884-658 TABLET 4 mg ORAL NDA authorized generic 27 sections
Candesartan cilexetil HUMAN PRESCRIPTION DRUG LABEL 1 49884-659 TABLET 8 mg ORAL NDA authorized generic 27 sections
Candesartan cilexetil HUMAN PRESCRIPTION DRUG LABEL 1 49884-660 TABLET 16 mg ORAL NDA authorized generic 27 sections
Candesartan cilexetil HUMAN PRESCRIPTION DRUG LABEL 1 49884-661 TABLET 32 mg ORAL NDA authorized generic 27 sections
ATACAND HUMAN PRESCRIPTION DRUG LABEL 1 54868-4413 TABLET 16 mg ORAL NDA 27 sections
ATACAND HUMAN PRESCRIPTION DRUG LABEL 1 54868-4612 TABLET 32 mg ORAL NDA 27 sections
ATACAND HCT HUMAN PRESCRIPTION DRUG LABEL 2 54868-4729 TABLET 16 mg ORAL NDA 22 sections
ATACAND HCT HUMAN PRESCRIPTION DRUG LABEL 2 54868-4869 TABLET 32 mg ORAL NDA 22 sections